Page 11 - Randomized Phase News Today

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of

New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies

Investegate announcements from NOVARTIS AG CHF0.50(REGD), New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

ABBVie will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology Annual Meeting in Atlanta, Georgia . "We are dedicated to transforming standards of care for people living with blood cancers," said Mohamed Zaki M.D., Ph.D, vice president and global head of oncology development, AbbVie. "The data we are presenting at the ASH Annual Meeting build on ...

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for...

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of...

Investegate announcements from Curium, Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

Investegate announcements from F. Hoffmann-La Roche Ltd, FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)

Data to be presented at the 2021 ISIRV-WHO Virtual ConferenceWALTHAM, Mass., Oct. 19, 2021data from the company's ongoing Phase 1 trial of ADG20 in healthy participants. "These new variant data further